Company profile
KODIAK SCIENCES INC.
NASDAQ:KODBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TARCOCIMAB TEDROMER | phase3 | — | 8 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06990399 | phase3 | recruiting | 2025-07-30 | 2027-04-01 | Kodiak Sciences Inc | A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK |
| NCT06996080 | phase3 | recruiting | 2025-07-16 | 2027-02-01 | Kodiak Sciences Inc | A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE |
| NCT04964089 | phase3 | completed | 2021-06-23 | 2023-03-28 | Kodiak Sciences Inc | A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) |
| NCT05066230 | phase3 | terminated | 2021-09-07 | 2023-08-03 | Kodiak Sciences Inc | A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR) |
| NCT04049266 | phase2_3 | terminated | 2019-10-08 | 2021-11-17 | Kodiak Sciences Inc | A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. |
FDA applications (0)
No records yet.